Literature DB >> 8914031

Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy.

G L Bakris1, J B Copley, N Vicknair, R Sadler, S Leurgans.   

Abstract

Treatment of hypertension with ACE inhibitors in diabetic patients reduces proteinuria and slows progression of nephropathy compared with agents that do not maintain declines in proteinuria. Calcium channel blockers (CCBs) have variable effects on proteinuria; their long-term effects on progression of diabetic nephropathy are not known. The current study examines the hypothesis that CCBs that maintain reductions in proteinuria slow progression of nephropathy associated with non-insulin dependent diabetes mellitus (NIDDM) by a degree comparable to ACE inhibitors, given similar levels of blood pressure control. To test this hypothesis we randomized 52 patients with NIDDM associated nephropathy and hypertension, mean age of 63 +/- 8 years, to either the ACE inhibitor, lisinopril (N = 18), nondihydropyridine CCBs (NDCCBs), verapamil SR (N = 8) or diltiazem SR (N = 10), or the beta blocker, atenolol (N = 16). Goal blood pressure was < or = 140/90 mm Hg. Patients were followed for a mean period of 63 +/- 7 months. The primary end point was change in creatinine clearance (CCr) slope in each group. There was no significant difference in mean arterial pressure reduction among the groups over the study period (P = 0.14). The mean rate of decline in CCr was greatest in the atenolol group (-3.48 ml/min/year/1.73 m2; P < 0.0001). There was no difference in the CCr slopes between lisinopril and NDCCBs groups (P = 0.36). Proteinuria was reduced to a similar extent in the lisinopril and NDCCBs groups (P > 0.99). Therefore, in persons with renal insufficiency secondary to NIDDM, similar levels of blood pressure control with either lisinopril or NDCCBs slowed progression of renal disease to a greater extent than atenolol. Moreover, this enhanced slowing of renal disease progression correlated with sustained and significant reductions in proteinuria, findings not observed in the atenolol group.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8914031     DOI: 10.1038/ki.1996.480

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  61 in total

1.  Managing hypertension in patients with renal disease and diabetes.

Authors:  A Bell
Journal:  CMAJ       Date:  2000-05-30       Impact factor: 8.262

2.  Managing hypertension in patients with renal disease and diabetes.

Authors:  R Grad; S Hanley
Journal:  CMAJ       Date:  2000-05-30       Impact factor: 8.262

3.  Access to the morning-after pill in BC.

Authors:  W D Gutowski
Journal:  CMAJ       Date:  2000-05-30       Impact factor: 8.262

Review 4.  What is the optimal strategy to intensify blood pressure control and prevent progression of renal failure?

Authors:  M Epstein; S Tobe
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

Review 5.  The need to lower systolic blood pressure.

Authors:  S Shrivastava; M S Kochar
Journal:  Curr Hypertens Rep       Date:  2000-10       Impact factor: 5.369

Review 6.  Nephrology: 4. Strategies for the care of adults with chronic kidney disease.

Authors:  Caroline Stigant; Lesley Stevens; Adeera Levin
Journal:  CMAJ       Date:  2003-06-10       Impact factor: 8.262

Review 7.  Microalbuminuria and diabetic cardiovascular disease.

Authors:  Richard J MacIsaac; Mark E Cooper
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

Review 8.  Treatment of hypertension in diabetic patients with nephropathy.

Authors:  R Komers; S Anderson
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

Review 9.  The choice of antihypertensive drugs in patients with diabetes: angiotensin II and beyond.

Authors:  Kambiz Kalantarinia; Helmy M Siragy
Journal:  Curr Diab Rep       Date:  2002-10       Impact factor: 4.810

Review 10.  Appropriate drug therapy for improving outcomes in diabetic nephropathy.

Authors:  Robert D Toto
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.